(Q39413086)

11 September 2017

Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells (English)

1 reference

11 September 2017

1 reference

J Tanizaki

1

1 reference

11 September 2017

I Okamoto

2

1 reference

11 September 2017

K Takezawa

3

1 reference

11 September 2017

K Sakai

4

1 reference

11 September 2017

K Azuma

5

1 reference

11 September 2017

K Kuwata

6

1 reference

11 September 2017

H Yamaguchi

7

1 reference

11 September 2017

E Hatashita

8

1 reference

11 September 2017

K Nishio

9

1 reference

11 September 2017

P A Janne

10

1 reference

11 September 2017

K Nakagawa

11

1 reference

11 September 2017

language of work or name

English

0 references

publication date

12 January 2012

1 reference

British Journal of Cancer

11 September 2017

1 reference

11 September 2017

106

1 reference

11 September 2017

4

1 reference

11 September 2017

763-767

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

The biology and treatment of EML4-ALK non-small cell lung cancer

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.

11 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

Role of ERK-BIM and STAT3-survivin signaling pathways in ALK inhibitor-induced apoptosis in EML4-ALK-positive lung cancer

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3322944

14 September 2017

Identifiers

DOI

10.1038/BJC.2011.586

1 reference

11 September 2017

1 reference

11 September 2017

PubMed publication ID

22240786

1 reference